EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE 
EMPOWERING MYELOMA ADVOCACY ACROSS EUROPE
Myeloma Patients Europe (MPE) is pleased to announce it has been appointed to the new Health Technology Assessment (HTA) Stakeholder Network of the European Commission. This means that MPE will be actively engaged and consulted in the implementation of the EU HTA Regulation.
Myeloma Patients Europe (MPE) has today launched a first-of-its-kind advocacy report on Addressing access barriers to myeloma clinical trials in Central and Eastern Europe (CEE).
Starting in December 2022, the HORIZON-funded project ASCERTAIN (Affordability and Sustainability improvements through new pricing, Cost- Effectiveness and Reimbursement models to Appraise innovative health technologies) will address the need of patients, physicians, payers, regulators, and manufacturers to improve the affordability and accessibility to innovative health technologies (including pharmaceuticals) in Europe. Affording newly approved innovative health technologies (IHTs) is challenging in many health systems.
According to a study published in Blood Advances, caregivers of patients undergoing a stem cell transplant cope with high caregiver burden, psychological distress, and worse quality of life.
Myeloma Patient Europe (MPE) has been aware of the lack of clinical trials opening in many Central and Eastern European (CEE) countries, as well as inequalities in access with CEE countries for participating in ongoing trials. To gather data on, and further understand the access situation, MPE conducted research on barriers and facilitators to clinical trials, with a specific focus on CEE countries. The research was completed under the guidance of MPE members from across the region through its CEE…
The American Society of Clinical Oncology Annual Meeting (ASCO2020) is the largest and one of the most important congresses for the oncology community. Many myeloma and AL amyloidosis updates were presented at this congress which was held from 29 to 31 May 2020. Two weeks later, the 25th edition of the European Hematology Association’s annual congress (EHA25 Virtual), one of the most important haematology congresses here in Europe, was held from 11 June to 21…
Dr Moshe Gatt, Hadassah Hebrew University Medical Center, Jerusalem (Israel) summarised for Myeloma Patients Europe (MPE) the main updates on AL amyloidosis presented at the American Society of Hematology (ASH) Annual Meeting held from 7 to 10 December 2019 in Orlando, Florida, USA.
MPE is looking for a Senior Office Assistant. Would you like to join the MPE team? Apply for this job offer by sending your CV and motivation letter to Ananda Plate . Full time / permanent Approx. 10 days of travel per year Munich, Germany Salary: 35.000-40.000 EUR GROSS per year
Myeloma Patients Europe (MPE) is holding another round of Myeloma Community Advisory Board (Myeloma-CAB) meetings from 17 – 18 November in Munich, Germany. The Myeloma-CAB focuses on providing patient perspectives and advice on clinical development in myeloma, challenges in access to myeloma medicines and patient engagement in myeloma research and development. These meeting ensure meaningful and systematic engagement with the patient community in Europe.
